Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 10% world market = $100M + two digits loyalty

<< Previous

Bullboard Posts

Next >>

Comment by Kazam1961on Feb 09, 2021 12:14pm

118 Views

Post# 32513584

RE:10% world market = $100M + two digits loyalty

Actuarial......Pumper, pumper, pumper, pumper.....$500./share? any credibility you may have has evapourated after this statemement...LOL, LOL, LOL
https://www.youtube.com/watch?v=KBxXrDvG-Yo We did a video for you buddy...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China